Premium
Irinotecan and temozolomide for treatment of neuroblastoma in a patient with renal failure on hemodialysis
Author(s) -
Armstrong Amy E.,
Dargart Jamie,
Reichek Jennifer,
Walterhouse David O.,
Matossian Debora,
Cohn Richard A.,
Gosiengfiao Yasmin
Publication year - 2014
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.24869
Subject(s) - medicine , irinotecan , hemodialysis , temozolomide , neuroblastoma , blood cancer , neutropenia , chemotherapy , surgery , cancer , colorectal cancer , biology , genetics , cell culture
Renal failure is a rare complication of neuroblastoma or its therapy. To our knowledge, no reports describe treatment of children with neuroblastoma with chemotherapy in the setting of renal failure and maintenance hemodialysis. We report a 6‐year‐old child with high‐risk neuroblastoma who developed renal failure requiring long‐term hemodialysis. She was subsequently treated with 13 cycles of intravenous irinotecan 20 mg/m 2 /day and oral temozolomide 100 mg/m 2 /day for 5 days before disease progression without any dose adjustments, transfusions, febrile neutropenia or diarrhea. This case demonstrates that irinotecan and temozolomide can be safely administered in children with renal failure requiring hemodialysis. Pediatr Blood Cancer 2014;61:949–950. © 2013 Wiley Periodicals, Inc.